- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00709488
Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
A Phase 1 Study to Evaluate the Safety and Effectiveness of Using the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Who Are Candidates for Interventional Therapy
Study Overview
Status
Detailed Description
The eligible patients will be enrolled into one of the three Litx™ treatment Cohorts (A, B or C)
All patients will undergo the procedure of Litx™ BPH Device placement into the prostate urethra.
Following the placement of the Litx™ BPH Device into the urethra, patients in Cohort A will be administered an intravenous dose of LS11 (talaporfin sodium) at 1 mg/kg by slow push over 3 - 5 minutes. Fifteen minutes after injection, each patient will be administered a 50 J total light dose, delivered at 20 mW/cm over a 42 minute time period.
Following the placement of the Litx™ BPH Device into the urethra, patients in Cohort B will receive LS11 intravenously at 1 mg/kg by slow push over 3 to 5 minutes. The light activation procedure is the same as that for Cohort A except that a light dose of 70 J will be delivered to each patient over a 58 minute time period.
Following the placement of the Litx™ BPH Device into the urethra, patients in Cohort C will receive LS11 intravenously at 1 mg/kg by slow push over 3 to 5 minutes. The light activation procedure is the same as that for Cohort A except that a light dose of 100 J will be delivered to each patient over a 83 minute time period.
Following the placement of the Litx™ BPH Device into the urethra, patients in Cohort D will receive LS11 intravenously at 1 mg/kg by slow push over 3 to 5 minutes. The light activation procedure is the same as that for Cohort C except that the active light emitting length is 20 mm instead of 10mm.
After 30 days, patients who have not experienced an improvement in symptoms, as determined by the investigator, may undergo an additional interventional therapy with continued follow-up per the protocol.
Four weeks following treatment of the last patient in the current cohort, the number of patients requiring surgical intervention for relief of primary symptoms will be assessed for futility of the protocol prior to commencing with treatment of the first patient in the next consecutive cohort.
Upon acceptable safety assessment four weeks after completing the last patient treatment in each cohort, the first patient in the next consecutive cohort may be treated.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alaska
-
Anchorage, Alaska, United States, 99508
- Alaska Clinical Research Center
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA School of Medicine, GU Clinical Trials Office
-
-
Oregon
-
Portland, Oregon, United States, 97205
- The Portland Clinic
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Urology San Antonio Research
-
-
Washington
-
Mountlake Terrace, Washington, United States, 98043
- Integrity Medical Research
-
Seattle, Washington, United States, 98104
- Seattle Urological Associates
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males, 50 years or older, who are on an alpha blocker and/or a 5-alpha reductase inhibitor or a combination, and are candidates for interventional therapy. Patients to continue on an alpha blocker and/or 5-alpha reductase inhibitor for at least one-month after the Litx™ treatment, then tapered off medication at physician's discretion.
- Patients who understand and have the ability to sign written informed consent prior to any study procedures and discontinuation of exclusionary medications.
- Patients with moderate to severe BPH bother score >3 requiring non-medication intervention.
- Patients with an IPSS1 Score of >15 points.
- Maximum urinary flow rate (Qmax) ≤15 mL/sec.
- Post void residual volume (PVR) ≤300 mL.
- Prostatic volume >50g by TRUS.
Exclusion Criteria:
- Patients with any previous minimally invasive or surgical intervention for BPH.
- Patients who have enrolled, or are currently enrolled in, another clinical trial for any disease within the past 30 days.
- Patients with an active urinary tract infection.
- Patients with a urethral stricture.
- Patients with a predominant middle lobe obstruction.
- Patients who have evidence or history of prostate or bladder cancer.
- Patients with a PSA of >10 ng/ml. If the PSA is 4-10 ng/ml, preliminary biopsy should be done within one-year prior to entry into the study to rule out prostate cancer.
- Patients who had a biopsy of the prostate within the past 6 weeks.
- Patients with bleeding diathesis.
- Patients with clinically significant renal or hepatic impairment.
- Patients with neurological conditions felt to affect the bladder or a history of a neurogenic or chronically decompensated bladder.
- Patients who daily use a pad or device for incontinence.
- Patients who had an episode of unstable angina pectoris, myocardial infarction, transient ischemic attack, or cerebrovascular accident (stroke) within the past 6 months, or peripheral arterial disease with intermittent claudication or Leriches syndrome.
- Patient has an interest in future fertility.
- Patients with prolonged QT interval at baseline or currently taking medications that prolong QT interval (prolonged QT interval defined as > 450 ms).
- Inadequate organ function as evidenced by the following: Platelet count <100,000/mm³; WBC <4,000/mm³; Neutrophils <1,800/mm³; Hemoglobin <10 g/dL; SGOT and SGPT >3 x ULN; Creatinine >1.2 mg/dL
- Known sensitivity to porphyrin-type drugs or known history of porphyria.
- Known sensitivity to antibiotics (i.e., levofloxacin, gentamicin, etc.).
- Inability to avoid sunlight after procedure during the first 2 weeks after LS11 administration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Litx™ BPH Therapy
|
LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
Other Names:
Placement of device in prostate urethra
Patients in Cohort A will receive 50 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort B will receive 70 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort C will receive 100 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort D will receive 100 J of light treatment (with the active light emitting length increased from 10mm to 20 mm) with 1 mg/kg LS11 administration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety of Litx™ BPH System by Recording of Adverse Events; Preliminary effectiveness of Litx™ BPH System by evaluating the International Prostate Symptom Score (IPSS) along with Bother Score (BS).
Time Frame: 9 months
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the effect of the Litx™ treatment following tests by: Maximum urinary flow rate (Qmax); Post void residual volume (PVR); Transrectal ultrasound (TRUS) to measure prostate size and treatment effect.
Time Frame: 9 months
|
9 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Sy-Shi Wang, PhD, Light Sciences Oncology, Inc
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LSO-OL008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lower Urinary Tract Symptoms
-
The Royal College of Surgeons of EnglandUniversity College, LondonCompletedUncomplicated Lower Urinary Tract Symptoms
-
National Taiwan University HospitalUnknownDisorder of the Lower Urinary TractTaiwan
-
ProVerum MedicalNot yet recruitingBPH With Symptomatic Lower Urinary Tract Symptoms
-
Baylor Research InstituteForte MedicalCompletedLower Urinary Tract Symptoms | Lower Urinary Tract InfectionUnited States
-
The University of Texas Medical Branch, GalvestonCompletedLower Urinary Tract Symptoms | Lower Gastrointestinal Tract Symptoms
-
Far Eastern Memorial HospitalCompletedPsychiatric Aspects in Women With Lower Urinary Tract SymptomsTaiwan
-
Jagiellonian UniversityPiotr ChlostaCompletedTo Evaluate Lower Urinary Tract Symptoms (LUTS) in PolandPoland
-
Boston Scientific CorporationTerminatedBPH | BPH With Urinary Obstruction | BPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsUnited States, Australia
-
Benaroya Research InstituteVirginia Mason Hospital/Medical CenterUnknownPain | BPH With Urinary Obstruction | BPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsUnited States
-
San Carlo di Nancy HospitalLampugnani Farmaceutici S.p.A. (Nerviano, Milan, Italy)CompletedBPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsItaly
Clinical Trials on Talaporfin sodium
-
University of California, IrvineBeckman Laser Institute University of California IrvineCompleted
-
Light Sciences OncologyCompletedCarcinoma, Hepatocellular | Liver NeoplasmsTaiwan, Hong Kong, Singapore
-
Children's Hospital of PhiladelphiaUnited States Department of DefenseTerminated
-
Light Sciences LLCTerminatedMacular Degeneration | Choroidal NeovascularizationUnited States
-
Light Sciences OncologyCompletedLower Urinary Tract Symptoms | Benign Prostatic HyperplasiaNew Zealand, Australia
-
Light Sciences OncologyCompletedGlioma | Glioblastoma Multiforme | Anaplastic AstrocytomaSerbia
-
Light Sciences OncologyMundipharma Research LimitedCompletedBenign Prostatic HyperplasiaUnited States
-
Light Sciences OncologyCompletedNeoplasm Metastasis | Colorectal Neoplasms | Liver Metastases | Neoplasm Recurrence, LocalSweden, India, Austria, Serbia, Germany, Romania, Croatia, Bosnia and Herzegovina, Italy, Latvia, Poland, Russian Federation, Ukraine
-
Light Sciences LLCCompletedNeoplasm Metastasis | Liver Neoplasms | Colorectal Neoplasms | Liver MetastasisUnited States
-
Light Sciences LLCCompletedNeoplasm Metastasis | Liver Neoplasms | Colorectal Neoplasms | Liver MetastasisUnited States, Germany